BioreclamationIVT is a trusted partner for the National Institutes of Health and other global leaders in a range of industries, including pharmaceuticals, cancer research centers, cosmetics and skin care.
Our goal is serve as your scientific partner for the cell-based assay services you need to support your pre-clinical drug and biologics development projects.
Case Study: Drug Testing on Explant Ovarian Cancer Cells
A leading global pharmaceutical company is developing a new drug therapy for ovarian cancer. They needed evidence to determine whether the drug could lower the survival rate of cancer cells from humans enough to warrant a clinical trial.
BioreclamationIVT designed and implemented a study with human ovarian cancer cells from fresh samples of serous carcinoma. The cancer cells were incubated with the experimental drug and then tested for levels of ATP to determine cell survival after treatment.
The study found the geomean IC50 value for the shown cells to be 218nM, which was within the target therapeutic range. With reports and data from the BioreclamationIVT study, the pharmaceutical company determined the drug did have potential to treat serous ovarian carcinoma. The results are being used in the decision-making process regarding clinical trials.
Case Study: Localization of Transgene on Metaphase Chromosomes
A current challenge for pharmaceutical companies is to understand the usability of specific cell lines for drug production.
BioreclamationIVT addresses the particular relevance of the copy number of drug-producing genes inserted into the cells and their position on the chromosomes.
A study by BioreclamationIVT reports close proximity of the gene to the chromosome ends in this case, which significantly reduces gene expression by the ‘telomere position effect’ (TPE). These findings can result in the selection of specific lines, representing significant cost savings in the drug development process.